
MT2013-06C : Treatment of graft Failure after HSCT

The primary purpose of this study is to record outcomes and patient characteristics in the Masonic Cancer Center and BMT databases for patients undergoing a second transplant using a haploidentical donor, an unrelated donor or umbilical cord blood. The data will be analyzed for transplant “milestones” such as time to blood count recovery (engraftment) and how patients are doing at 3 months and 6 months after the transplant. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.
• patients with primary or secondary HSCT graft failure
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
• uncontrolled infection at the time of transplant
• patients with Fanconi Anemia or other DNA breakage syndromes
Drug: Cyclophosphamide, Drug: Fludarabine, Biological: Hematopoietic stem cell infusion, Radiation: Total Body Irradiation
Clinics and Surgery Center (CSC), Failure, Hematopoietic Stem Cell Transplantation, HSCT